1 |
Synthesis and anticancer activity evaluation of η5-C5(CH3)4R ruthenium complexes bearing chelating diphosphine ligandsRodríguez-Bárzano, A., Lord, Rianne M., Basri, A.M., Phillips, Roger M., Blacker, A.J., McGowan, P.C. 05 January 2015 (has links)
Yes / The complexes [RuCp*(PP)Cl] (Cp* = C5Me5; [1], PP = dppm; [4], PP = Xantphos), [RuCp#(PP)Cl] (Cp# =
C5Me4(CH2)5OH; [2], PP = dppm; [5], PP = Xantphos) and [RuCp*(dppm)(CH3CN)][SbF6] [3] were synthesized
and evaluated in vitro as anticancer agents. Compounds 1–3 gave nanomolar IC50 values against
normoxic A2780 and HT-29 cell lines, and were also tested against hypoxic HT-29 cells, maintaining their
high activity. Complex 3 yielded an IC50 value of 0.55 ± 0.03 μM under a 0.1% O2 concentration.
|
Page generated in 0.0785 seconds